Quoin Pharmaceuticals Ltd ADR (QNRX): Next-Year EPS Estimate 54.84%
As of 2026-07-17, Quoin Pharmaceuticals Ltd ADR (QNRX) has a next-year EPS growth estimate of 54.84%. Featured in 4 EPS revision reports, most recently on 2026-07-02.
On 2026-06-23, analyst consensus for QNRX's next-year EPS growth shifted from 45.37% to 54.84% — a positive change of 9.47 percentage points. The revised estimate has been sustained across 19 subsequent trading sessions. Current-year growth is projected at 57.06%.
What's Driving This
The primary driver of QNRX’s rise is a 9.47 percentage-point upgrade in next-year EPS growth estimates (to 54.84%) on June 23, 2026. This revision was plausibly catalyzed by the FDA’s conditional approval of the brand name QYLEKI for QRX003 and a constructive Type C meeting for the drug in Netherton syndrome, both announced in recent headlines. The upward momentum has continued following these regulatory milestones.
Generated 2026-07-17 from news as of 2026-07-17
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 54.84%
- EPS growth this year
- 57.06%
- EPS next quarter (est)
- -$1.61
- Last price
- $4.24
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-17 | 54.84% | 57.06% | -$1.61 | $4.24 |
| 2026-07-16 | 54.84% | 57.06% | -$1.61 | $4.16 |
| 2026-07-15 | 54.84% | 57.06% | -$1.61 | $4.21 |
| 2026-07-14 | 54.84% | 57.06% | -$1.61 | $4.35 |
| 2026-07-13 | 54.84% | 57.06% | -$1.61 | $4.23 |
| 2026-07-12 | 54.84% | 57.06% | -$1.61 | $4.45 |
| 2026-07-09 | 54.84% | 57.06% | -$1.61 | $4.67 |
| 2026-07-08 | 54.84% | 57.06% | -$1.61 | $4.72 |
| 2026-07-07 | 54.84% | 57.06% | -$1.61 | $4.80 |
| 2026-07-06 | 54.84% | 57.06% | -$1.61 | $4.60 |
| 2026-07-05 | 54.84% | 57.06% | -$1.61 | $4.58 |
| 2026-07-02 | 54.84% | 57.06% | -$1.61 | $4.58 |
| 2026-07-01 | 54.84% | 57.06% | -$1.61 | $4.71 |
| 2026-06-30 | 54.84% | 57.06% | -$1.61 | $4.84 |
| 2026-06-29 | 54.84% | 57.06% | -$1.61 | $4.55 |
| 2026-06-28 | 54.84% | 57.06% | -$1.61 | $4.45 |
| 2026-06-25 | 54.84% | 57.06% | -$1.61 | $4.20 |
| 2026-06-24 | 54.84% | 57.06% | -$1.61 | $3.83 |
| 2026-06-23 | 54.84% | 57.06% | -$1.61 | $3.25 |
| 2026-06-22 | 45.37% | 56.22% | -$1.61 | $4.41 |
| 2026-06-21 | 45.37% | 56.22% | -$1.61 | $4.65 |
| 2026-06-18 | 45.37% | 56.22% | -$1.61 | $4.65 |
| 2026-06-17 | 45.37% | 56.22% | -$1.61 | $4.62 |
| 2026-06-16 | 45.37% | 56.22% | -$1.61 | $4.46 |
| 2026-06-15 | 45.37% | 56.22% | -$1.61 | $4.65 |
| 2026-06-14 | 45.37% | 56.22% | -$1.61 | $4.20 |
| 2026-06-11 | 45.37% | 56.22% | -$1.61 | $4.70 |
| 2026-06-10 | 45.37% | 56.22% | -$1.61 | $5.06 |
| 2026-06-09 | 45.37% | 56.22% | -$1.61 | $4.95 |
| 2026-06-08 | 45.37% | 56.22% | -$1.61 | $4.57 |
Reports Featuring QNRX
- 2026-07-02
Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
- 2026-07-01
Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
- 2026-06-30
QNRX surges 48.9% as EPS revision signal precedes price breakout; HELP, ACMR also climb
- 2026-06-29
EPS Revision Bonanza: LILA +61%, HELP +47%, BDSX +42% Lead Surge
Recent News
- Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI as the Proposed Brand Name for QRX003 for Netherton SyndromeGlobeNewswire
- Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswire
- Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton SyndromeGlobeNewswire
Screen Performance
Aggregate stats across all 1864 tickers our top-EPS-revision screen has flagged over the past 107 days.
- Median return since detection
- +2.5%
- % of tickers in the green
- 55%
- Median return on winners
- +20.8%
- Large revisions captured
- 1048
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Quoin Pharmaceuticals Ltd ADR's next-year EPS growth estimate?▾
As of 2026-07-17, Quoin Pharmaceuticals Ltd ADR (QNRX) has a next-year EPS growth estimate of 54.84%, based on analyst consensus.
When was the latest EPS estimate revision for QNRX?▾
The most recent revision occurred on 2026-06-23, when analysts adjusted the next-year EPS growth estimate from 45.37% to 54.84%.
What sector and industry does Quoin Pharmaceuticals Ltd ADR belong to?▾
Quoin Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. QNRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Quoin Pharmaceuticals Ltd ADR (QNRX) appears here because it was detected by our daily top-EPS-revision-performer screen.